Comparing Different Anti-angiogenic Agents and TKI Combinations in EGFR-mutated Advanced NSCLC: a Retrospective Study

被引：0
|
作者：
Sun, R. -L. [1 ]
Liao, Y. -T. [1 ]
Shen, C. -I. [1 ,2 ]
Chiang, C. -L. [1 ,2 ]
Tseng, Y. -H. [1 ,2 ]
Hsiao, T. -H. [1 ]
Chao, H. -S. [1 ,2 ]
Luo, Y. -H. [1 ,2 ]
Chen, Y. -M. [1 ,2 ]
Huang, H. -C. [1 ,2 ]
机构：
[1] Taipei Vet Gen Hosp, Taipei, Taiwan
[2] Natl Yang Ming Chiao Tung Univ, Sch Med, Taipei, Taiwan
来源：
JOURNAL OF THORACIC ONCOLOGY | 2023年 / 18卷 / 11期
关键词：
non-small cell lung cancer; anti-angiogenesis therapy; epidermal growth factor receptor;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
EP12.01-12
引用
收藏
页码：S645 / S645
页数：1
相关论文
共 50 条
  • [1] EGFR-TKI plus /- Antiangiogenics for EGFR-mutated Advanced NSCLC
    da Silva, L. L.
    Matsas, S.
    Aguiar, P., Jr.
    Taveira, G. M. T.
    Barcelos, I. F.
    Lopes, G. L., Jr.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S416 - S417
  • [2] EGFR-TKI Combined with Pemetrexed versus EGFR-TKI Monotherapy in Advanced EGFR-Mutated NSCLC: A Prospective, Randomized, Exploratory Study
    Gu, Weiguang
    Zhang, Hua
    Lu, Yiyu
    Li, Minjing
    Yang, Shuang
    Liang, Jianmiao
    Ye, Zhijian
    Li, Zhihua
    He, Minhong
    Shi, Xiaoliang
    Wang, Fei
    You, Dong
    Gu, Weiquan
    Feng, Weineng
    CANCER RESEARCH AND TREATMENT, 2023, 55 (03): : 841 - 850
  • [3] Immunotherapy with chemotherapy and anti-angiogenic therapy for EGFR mutated NSCLC: challenging the dogma
    Tan, Aaron C.
    Kobayashi, Keigo
    Saw, Stephanie P. L.
    Tan, Daniel S. W.
    Lim, Darren Wan-Teck
    EXPERT REVIEW OF ANTICANCER THERAPY, 2023, 23 (02) : 117 - 120
  • [4] Effect of smoking habits on the efficacy of EGFR-TKI plus anti-angiogenic agent in advanced EGFR-mutant NSCLC
    Qin, Bao-Dong
    Jiao, Xiao-Dong
    Wang, Yan
    Wu, Ying
    Ling, Yan
    Liu, Ke
    Zang, Yuan-Sheng
    LUNG CANCER, 2022, 170 : 91 - 97
  • [5] Outcome of Advanced EGFR-Mutated NSCLC Patients with MET-Driven Acquired Resistance to EGFR TKI. Results of the METEORE Study
    Baldacci, Simon
    Mazieres, Julien
    Tomasini, Pascale
    Girard, Nicolas
    Guisier, Florian
    Valette, Clarisse Audigier
    Monnet, Isabelle
    Wislez, Marie
    Perol, Maurice
    Do, Pascal
    Dansin, Eric
    Leduc, Charlotte
    Leprieur, Etienne Giroux
    Moro-Sibilot, Denis
    Kherrouche, Zoulika
    Labreuche, Julien
    Cortot, Alexis
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1219 - S1220
  • [6] Osimertinib Versus Comparator EGFR TKI as First-Line Treatment for EGFR-Mutated Advanced NSCLC: FLAURA China, A Randomized Study
    Cheng, Ying
    He, Yong
    Li, Wei
    Zhang, He-long
    Zhou, Qing
    Wang, Buhai
    Liu, Chunling
    Walding, Andrew
    Saggese, Matilde
    Huang, Xiangning
    Fan, Minhao
    Wang, Jia
    Ramalingam, Suresh S.
    TARGETED ONCOLOGY, 2021, 16 (02) : 165 - 176
  • [7] Osimertinib Versus Comparator EGFR TKI as First-Line Treatment for EGFR-Mutated Advanced NSCLC: FLAURA China, A Randomized Study
    Ying Cheng
    Yong He
    Wei Li
    He-long Zhang
    Qing Zhou
    Buhai Wang
    Chunling Liu
    Andrew Walding
    Matilde Saggese
    Xiangning Huang
    Minhao Fan
    Jia Wang
    Suresh S. Ramalingam
    Targeted Oncology, 2021, 16 : 165 - 176
  • [8] A retrospective analysis of locally advanced EGFR-mutated NSCLC patients with durvalumab after chemoradiotherapy
    Uchida, Yoshiyasu
    Ninomiya, Takashi
    Harada, Daijiro
    Kozuki, Toshiyuki
    ANNALS OF ONCOLOGY, 2022, 33 : S488 - S488
  • [9] EGFR-TKI Plus Anti-Angiogenic Drugs in EGFR-Mutated Non-Small Cell Lung Cancer: A Meta-Analysis of Randomized Clinical Trials
    Conforti, Fabio
    Pala, Laura
    Bagnardi, Vincenzo
    Specchia, Claudia
    Oriecuia, Chiara
    Marra, Antonio
    Zagami, Paola
    Morganti, Stefania
    Tarantino, Paolo
    Catania, Chiara
    De Marinis, Filippo
    Queirolo, Paola
    De Pas, Tommaso
    JNCI CANCER SPECTRUM, 2020, 4 (06)
  • [10] A bayesian network comparison of different agents or regimens as first-line treatment for advanced EGFR-mutated NSCLC.
    Liang, Wenhua
    He, Qihua
    Zhang, Jianrong
    Jiang, Long
    Zhou, Caicun
    He, Jianxing
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
12345